This report was recently updated on November 15 2024 with the latest and most recent
market numbers
Global Myocardial Infarction Market Size, Trends & Analysis - Forecasts to 2029 By Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, and Thrombolytics), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global myocardial infarction (MI) market is estimated to exhibit a CAGR of 6.4% from 2024 to 2029.
The primary factors propelling the market growth are the increasing cases of heart attacks and the rising cases of high blood pressure, obesity, and diabetes. The growing prevalence of heart attacks fuels research and development efforts focused on cardioprotective medications designed to preserve heart muscle function, reduce myocardial damage, and improve patient outcomes post-infarction. For instance, the Centers for Disease Control and Prevention (CDC) estimated that around 695,000 Americans lost their lives to heart disease in 2021, accounting for 1 in every five fatalities.
The market is expected to grow due to the increasing focus on secondary myocardial infarction prevention measures and personalized medication. The care of acute coronary syndrome (ACS), which includes unstable angina and non-ST segment elevation myocardial infarction (NSTEMI), is covered by secondary preventive strategies. Advancements in acute coronary syndrome therapies, such as antiplatelet agents, anticoagulants, and invasive coronary interventions, contribute to the growth of the myocardial infarction market. Moreover, secondary prevention strategies aim to reduce the risk of cardiac ischemia and subsequent myocardial infarction. Research efforts in cardiac ischemia treatment options for cardiac ischemia, including pharmacological agents, medical devices, coronary artery disease interventions, and ischemic heart disease pathways.
The market is growing due to the rising launches of cardiac rehabilitation programs and the utilization of telemedicine and remote monitoring technologies. Governments and health organizations, including the Centers for Disease Control and Prevention (CDC), must take proactive measures to address the rising burden of cardiovascular diseases. This includes funding research projects, implementing public health campaigns, and establishing policies to improve access to cardiovascular care, all of which drive the myocardial infarction market.
There is an opportunity to develop novel reperfusion therapies for MI aimed at restoring blood flow to the ischemic myocardium promptly and effectively. To improve reperfusion results, research and development efforts are concentrated on cutting-edge strategies such as novel thrombolytic medicines, next-generation PCI procedures, and adjuvant therapy. Additionally, opportunities exist for the development of next-generation antiplatelet agents with improved efficacy, safety profiles, and mechanisms of action. Targeted therapies that address specific platelet activation pathways could offer significant advantages in optimizing antiplatelet therapy for heart attack patients.
However, stringent regulatory requirements and patient compliance issues may impede market growth during the forecast period.
The antiplatelet agents segment is anticipated to dominate the market over the forecast period. For both acute and long-term therapy of MI, antiplatelet agents such as aspirin, clopidogrel, and ticagrelor are frequently recommended. They have become widely accepted as the standard of care for MI patients due to their proven ability to lower cardiovascular events.
The analgesics segment is expected to be the fastest-growing segment from 2024 to 2029. Analgesics, particularly NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), play a crucial role in managing the pain associated with myocardial infarction (MI). Chest pain, a hallmark symptom of MI, necessitates effective pain relief for patient comfort and improved outcomes.
The oral segment is expected to hold the largest share of the market over the forecast period. In acute and long-term care of myocardial infarction (MI), oral administration provides patients with a familiar, simple way to take their medications. Both patients and healthcare professionals generally choose oral drugs due to this convenience feature.
The injectable segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. Given their quick beginning of action, injectable drugs are beneficial in the acute therapy of myocardial infarction (MI) when prompt intervention is frequently essential. When drugs are administered intravenously instead of orally, they can be quickly delivered into the bloodstream and have a greater therapeutic impact.
The hospital pharmacies segment is expected to hold the largest share of the market over the forecast period. When it comes to the acute treatment of myocardial infarction (MI), hospital pharmacies are essential as prompt drug delivery is essential to improving patient outcomes. Hospitals are the primary place of care for MI patients. Hospital pharmacists are well-equipped to handle these patients' urgent pharmaceutical demands, including supplying emergency drugs and enabling quick treatment commencement.
The online pharmacies segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. Patients can get prescriptions from the convenience of their homes and have them delivered right to their door through online pharmacies, which provide unrivaled convenience and accessibility. The convenience component is also essential for people who have heart-related diseases such as myocardial infarction (MI), as they may have trouble visiting traditional brick-and-mortar pharmacies or have mobility issues.
North America is expected to be the largest region in the global market. The growth is attributed to North America's sophisticated healthcare infrastructure, which includes cutting-edge clinics, hospitals, and research facilities. This infrastructure promotes early detection, timely intervention, and efficient management of MI, which propels the growth of the myocardial infarction markets.
Asia Pacific is anticipated to witness rapid growth during the forecast period. Government initiatives and healthcare reforms to improve healthcare access, affordability, and quality drive market growth in the Asia Pacific region. Public health campaigns, disease preventive initiatives, and universal health care are instances of initiatives that increase public awareness of myocardial infarction risk factors and support the early detection and treatment of MI.
Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA, among others, are some of the key players in the global myocardial infarction market.
Please note: This is not an exhaustive list of companies profiled in the report.
In April 2024, results of the EMPACT-MI phase III trial, which examined Jardiance (empagliflozin)'s impact on a 10% reduction in the risk of heart failure hospitalization and death in people after a heart attack, were released by Boehringer Ingelheim International GmbH.
In September 2023, three investigator-sponsored Phase III clinical trials assessing Kerendia (finerenone) as a heart failure therapy have been added by Bayer AG. For adult patients with chronic kidney disease associated with type 2 diabetes, the US Food and Drug Administration (FDA) has approved Kerendia to lower the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MYOCARDIAL INFARCTION MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL MYOCARDIAL INFARCTION MARKET, BY DRUG CLASS
4.1 Introduction
4.2 Myocardial Infarction Market: Drug Class Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Antiplatelet Agents
4.4.1 Antiplatelet Agents Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Glycoprotein IIb/IIIa Inhibitors
4.5.1 Glycoprotein IIb/IIIa Inhibitors Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Antithrombotic Agents
4.6.1 Antithrombotic Agents Market Estimates and Forecast, 2021-2029 (USD Million)
4.7 Beta-adrenergic Blockers
4.7.1 Beta-adrenergic Blockers Market Estimates and Forecast, 2021-2029 (USD Million)
4.8 Vasodilators
4.8.1 Vasodilators Market Estimates and Forecast, 2021-2029 (USD Million)
4.9 Angiotensin-converting Enzyme (ACE) Inhibitors
4.9.1 Angiotensin-converting Enzyme (ACE) Inhibitors Market Estimates and Forecast, 2021-2029 (USD Million)
4.10 Angiotensin-receptor Blockers
4.10.1 Angiotensin-receptor Blockers Market Estimates and Forecast, 2021-2029 (USD Million)
4.11 Analgesics
4.11.1 Analgesics Market Estimates and Forecast, 2021-2029 (USD Million)
4.12 Thrombolytics
4.12.1 Thrombolytics Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL MYOCARDIAL INFARCTION MARKET, BY ROUTE OF ADMINISTRATION
5.1 Introduction
5.2 Myocardial Infarction Market: Route of Administration Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Oral
5.4.1 Oral Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Injectable
5.5.1 Injectable Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL MYOCARDIAL INFARCTION MARKET, BY DISTRIBUTION CHANNEL
6.1 Introduction
6.2 Myocardial Infarction Market: Distribution Channel Scope Key Takeaways
6.3 Revenue Growth Analysis, 2023 & 2029
6.4 Hospital Pharmacies
6.4.1 Hospital Pharmacies Market Estimates and Forecast, 2021-2029 (USD Million)
6.5 Retail Pharmacies
6.5.1 Retail Pharmacies Market Estimates and Forecast, 2021-2029 (USD Million)
6.6 Online Pharmacies
6.6.1 Online Pharmacies Market Estimates and Forecast, 2021-2029 (USD Million)
7 GLOBAL MYOCARDIAL INFARCTION MARKET, BY REGION
7.1 Introduction
7.2 North America Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.1 By Drug Class
7.2.2 By Route of Administration
7.2.3 By Distribution Channel
7.2.4 By Country
7.2.4.1 U.S. Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.1.1 By Drug Class
7.2.4.1.2 By Route of Administration
7.2.4.1.3 By Distribution Channel
7.2.4.2 Canada Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.2.1 By Drug Class
7.2.4.2.2 By Route of Administration
7.2.4.2.3 By Distribution Channel
7.2.4.3 Mexico Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.3.1 By Drug Class
7.2.4.3.2 By Route of Administration
7.2.4.3.3 By Distribution Channel
7.3 Europe Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.1 By Drug Class
7.3.2 By Route of Administration
7.3.3 By Distribution Channel
7.3.4 By Country
7.3.4.1 Germany Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.1.1 By Drug Class
7.3.4.1.2 By Route of Administration
7.3.4.1.3 By Distribution Channel
7.3.4.2 U.K. Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.2.1 By Drug Class
7.3.4.2.2 By Route of Administration
7.3.4.2.3 By Distribution Channel
7.3.4.3 France Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.3.1 By Drug Class
7.3.4.3.2 By Route of Administration
7.3.4.3.3 By Distribution Channel
7.3.4.4 Italy Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.4.1 By Drug Class
7.3.4.4.2 By Route of Administration
7.2.4.4.3 By Distribution Channel
7.3.4.5 Spain Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.5.1 By Drug Class
7.3.4.5.2 By Route of Administration
7.2.4.5.3 By Distribution Channel
7.3.4.6 Netherlands Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.6.1 By Drug Class
7.3.4.6.2 By Route of Administration
7.2.4.6.3 By Distribution Channel
7.3.4.7 Rest of Europe Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.7.1 By Drug Class
7.3.4.7.2 By Route of Administration
7.2.4.7.3 By Distribution Channel
7.4 Asia Pacific Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.1 By Drug Class
7.4.2 By Route of Administration
7.4.3 By Distribution Channel
7.4.4 By Country
7.4.4.1 China Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.1.1 By Drug Class
7.4.4.1.2 By Route of Administration
7.4.4.1.3 By Distribution Channel
7.4.4.2 Japan Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.2.1 By Drug Class
7.4.4.2.2 By Route of Administration
7.4.4.2.3 By Distribution Channel
7.4.4.3 India Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.3.1 By Drug Class
7.4.4.3.2 By Route of Administration
7.4.4.3.3 By Distribution Channel
7.4.4.4 South Korea Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.4.1 By Drug Class
7.4.4.4.2 By Route of Administration
7.4.4.4.3 By Distribution Channel
7.4.4.5 Singapore Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.5.1 By Drug Class
7.4.4.5.2 By Route of Administration
7.4.4.5.3 By Distribution Channel
7.4.4.6 Malaysia Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.6.1 By Drug Class
7.4.4.6.2 By Route of Administration
7.4.4.6.3 By Distribution Channel
7.4.4.7 Thailand Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.7.1 By Drug Class
7.4.4.7.2 By Route of Administration
7.4.4.7.3 By Distribution Channel
7.4.4.8 Indonesia Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.8.1 By Drug Class
7.4.4.8.2 By Route of Administration
7.4.4.8.3 By Distribution Channel
7.4.4.9 Vietnam Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.9.1 By Drug Class
7.4.4.9.2 By Route of Administration
7.4.4.9.3 By Distribution Channel
7.4.4.10 Taiwan Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.10.1 By Drug Class
7.4.4.10.2 By Route of Administration
7.4.4.10.3 By Distribution Channel
7.4.4.11 Rest of Asia Pacific Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.11.1 By Drug Class
7.4.4.11.2 By Route of Administration
7.4.4.11.3 By Distribution Channel
7.5 Middle East and Africa Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.1 By Drug Class
7.5.2 By Route of Administration
7.5.3 By Distribution Channel
7.5.4 By Country
7.5.4.1 Saudi Arabia Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.1.1 By Drug Class
7.5.4.1.2 By Route of Administration
7.5.4.1.3 By Distribution Channel
7.5.4.2 U.A.E. Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.2.1 By Drug Class
7.5.4.2.2 By Route of Administration
7.5.4.2.3 By Distribution Channel
7.5.4.3 Israel Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.3.1 By Drug Class
7.5.4.3.2 By Route of Administration
7.5.4.3.3 By Distribution Channel
7.5.4.4 South Africa Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.4.1 By Drug Class
7.5.4.4.2 By Route of Administration
7.5.4.4.3 By Distribution Channel
7.5.4.5 Rest of Middle East and Africa Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.5.1 By Drug Class
7.5.4.5.2 By Route of Administration
7.5.4.5.2 By Distribution Channel
7.6 Central and South America Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.1 By Drug Class
7.6.2 By Route of Administration
7.6.3 By Distribution Channel
7.6.4 By Country
7.6.4.1 Brazil Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.1.1 By Drug Class
7.6.4.1.2 By Route of Administration
7.6.4.1.3 By Distribution Channel
7.6.4.2 Argentina Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.2.1 By Drug Class
7.6.4.2.2 By Route of Administration
7.6.4.2.3 By Distribution Channel
7.6.4.3 Chile Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.3.1 By Drug Class
7.6.4.3.2 By Route of Administration
7.6.4.3.3 By Distribution Channel
7.6.4.4 Rest of Central and South America Myocardial Infarction Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.4.1 By Drug Class
7.6.4.4.2 By Route of Administration
7.6.4.4.3 By Distribution Channel
8 COMPETITIVE LANDCAPE
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.2.1 Market Leaders
8.2.2 Market Visionaries
8.2.3 Market Challengers
8.2.4 Niche Market Players
8.3 Vendor Landscape
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Rest of the World
8.4 Company Profiles
8.4.1 Bristol-Myers Squibb Co.
8.4.1.1 Business Description & Financial Analysis
8.4.1.2 SWOT Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2 Bayer AG
8.4.2.1 Business Description & Financial Analysis
8.4.2.2 SWOT Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 Johnson & Johnson Services Inc.
8.4.3.1 Business Description & Financial Analysis
8.4.3.2 SWOT Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4 Sanofi S.A.
8.4.4.1 Business Description & Financial Analysis
8.4.4.2 SWOT Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Novartis International AG
8.4.5.1 Business Description & Financial Analysis
8.4.5.2 SWOT Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.6 ASTRAZENECA PLC.
8.4.6.1 Business Description & Financial Analysis
8.4.6.2 SWOT Analysis
8.4.6.3 Products & Services Offered
8.4.6.4 Strategic Alliances between Business Partners
8.4.7 Daiichi Sankyo Co Ltd
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8 Boehringer Ingelheim International GmbH
8.4.8.1 Business Description & Financial Analysis
8.4.8.2 SWOT Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 Pfizer Inc.
8.4.9.1 Business Description & Financial Analysis
8.4.9.2 SWOT Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10 Merck KGaA
8.4.10.1 Business Description & Financial Analysis
8.4.10.2 SWOT Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
8.4.11 Other Companies
8.4.11.1 Business Description & Financial Analysis
8.4.11.2 SWOT Analysis
8.4.11.3 Products & Services Offered
8.4.11.4 Strategic Alliances between Business Partners
9 RESEARCH METHODOLOGY
9.1 Market Introduction
9.1.1 Market Definition
9.1.2 Market Scope & Segmentation
9.2 Information Procurement
9.2.1 Secondary Research
9.2.1.1 Purchased Databases
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2 Primary Research
9.2.2.1 Various Types of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.3 Primary Stakeholders
9.2.2.4 Discussion Guide for Primary Participants
9.2.3 Expert Panels
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4 Paid Local Experts
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3 Market Estimation
9.3.1 Top-Down Approach
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2 Bottom Up Approach
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Type Sales
9.4 Data Triangulation
9.4.1 Data Collection
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.4.3 Cluster Analysis
9.5 Analysis and Output
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
9.7.1 Research Assumptions
9.7.2 Research Limitations
LIST OF TABLES
1 Global Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Mllion)
2 Antiplatelet Agents Market, By Region, 2021-2029 (USD Mllion)
3 Glycoprotein IIb/IIIa Inhibitors Market, By Region, 2021-2029 (USD Mllion)
4 Antithrombotic Agents Market, By Region, 2021-2029 (USD Mllion)
5 Beta-adrenergic Blockers Market, By Region, 2021-2029 (USD Mllion)
6 Vasodilators Market, By Region, 2021-2029 (USD Mllion)
7 Angiotensin-converting Enzyme (ACE) Inhibitors Market, By Region, 2021-2029 (USD Mllion)
8 Angiotensin-receptor Blockers Market, By Region, 2021-2029 (USD Mllion)
9 Analgesics Market, By Region, 2021-2029 (USD Mllion)
10 Thrombolytics Market, By Region, 2021-2029 (USD Mllion)
11 Global Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Mllion)
12 Oral Market, By Region, 2021-2029 (USD Mllion)
13 Injectable Market, By Region, 2021-2029 (USD Mllion)
14 Global Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Mllion)
15 Hospital Pharmacies Market, By Region, 2021-2029 (USD Mllion)
16 Retail Pharmacies Market, By Region, 2021-2029 (USD Mllion)
17 Online Pharmacies Market, By Region, 2021-2029 (USD Mllion)
18 Regional Analysis, 2021-2029 (USD Mllion)
19 North America Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
20 North America Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
21 North America Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
22 North America Myocardial Infarction Market, By Country, 2021-2029 (USD Million)
23 U.S. Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
24 U.S. Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
25 U.S. Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
26 Canada Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
27 Canada Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
28 Canada Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
29 Mexico Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
30 Mexico Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
31 Mexico Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
32 Europe Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
33 Europe Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
34 Europe Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
35 Europe Myocardial Infarction Market, By Country 2021-2029 (USD Million)
36 Germany Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
37 Germany Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
38 Germany Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
39 U.K Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
40 U.K Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
41 U.K Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
42 France Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
43 France Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
44 France Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
45 Italy Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
46 Italy Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
47 Italy Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
48 Spain Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
49 Spain Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
50 Spain Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
51 Netherlands Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
52 Netherlands Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
53 Netherlands Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
54 Rest Of Europe Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
55 Rest Of Europe Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
56 Rest of Europe Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
57 Asia Pacific Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
58 Asia Pacific Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
59 Asia Pacific Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
60 Asia Pacific Myocardial Infarction Market, By Country, 2021-2029 (USD Million)
61 China Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
62 China Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
63 China Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
64 India Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
65 India Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
66 India Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
67 Japan Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
68 Japan Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
69 Japan Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
70 South Korea Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
71 South Korea Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
72 South Korea Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
73 malaysia Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
74 malaysia Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
75 malaysia Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
76 Thailand Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
77 Thailand Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
78 Thailand Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
79 Indonesia Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
80 Indonesia Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
81 Indonesia Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
82 Vietnam Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
83 Vietnam Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
84 Vietnam Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
85 Taiwan Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
86 Taiwan Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
87 Taiwan Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
88 Rest of Asia Pacific Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
89 Rest of Asia Pacific Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
90 Rest of Asia Pacific Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
91 Middle East and Africa Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
92 Middle East and Africa Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
93 Middle East and Africa Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
94 Middle East and Africa Myocardial Infarction Market, By Country, 2021-2029 (USD Million)
95 Saudi Arabia Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
96 Saudi Arabia Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
97 Saudi Arabia Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
98 UAE Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
99 UAE Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
100 UAE Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
101 Israel Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
102 Israel Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
103 Israel Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
104 South Africa Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
105 South Africa Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
106 South Africa Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
107 Rest of Middle East and Africa Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
108 Rest of Middle East and Africa Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
109 Rest of Middle East and Africa Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
110 Central and South America Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
111 Central and South America Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
112 Central and South America Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
113 Central and South America Myocardial Infarction Market, By Country, 2021-2029 (USD Million)
114 Brazil Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
115 Brazil Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
116 Brazil Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
117 Argentina Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
118 Argentina Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
119 Argentina Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
120 Chile Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
121 Chile Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
122 Chile Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
123 Rest of Central and South America Myocardial Infarction Market, By Drug Class, 2021-2029 (USD Million)
124 Rest of Central and South America Myocardial Infarction Market, By Route of Administration, 2021-2029 (USD Million)
125 Rest of Central and South America Myocardial Infarction Market, By Distribution Channel, 2021-2029 (USD Million)
126 Bristol-Myers Squibb Co.: Products & Services Offering
127 Bayer AG: Products & Services Offering
128 Johnson & Johnson Services Inc.: Products & Services Offering
129 Sanofi S.A.: Products & Services Offering
130 Novartis International AG: Products & Services Offering
131 ASTRAZENECA PLC.: Products & Services Offering
132 Daiichi Sankyo Co Ltd: Products & Services Offering
133 Boehringer Ingelheim International GmbH: Products & Services Offering
134 Pfizer Inc., Inc: Products & Services Offering
135 Merck KGaA: Products & Services Offering
136 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Myocardial Infarction Market Overview
2 Global Myocardial Infarction Market Value From 2021-2029 (USD Mllion)
3 Global Myocardial Infarction Market Share, By Drug Class (2023)
4 Global Myocardial Infarction Market Share, By Route of Administration (2023)
5 Global Myocardial Infarction Market Share, By Distribution Channel (2023)
6 Global Myocardial Infarction Market, By Region (Asia Pacific Market)
7 Technological Trends In Global Myocardial Infarction Market
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global Myocardial Infarction Market
11 Impact Of Challenges On The Global Myocardial Infarction Market
12 Porter’s Five Forces Analysis
13 Global Myocardial Infarction Market: By Drug Class Scope Key Takeaways
14 Global Myocardial Infarction Market, By Drug Class Segment: Revenue Growth Analysis
15 Antiplatelet Agents Market, By Region, 2021-2029 (USD Mllion)
16 Glycoprotein IIb/IIIa Inhibitors Market, By Region, 2021-2029 (USD Mllion)
17 Antithrombotic Agents Market, By Region, 2021-2029 (USD Mllion)
18 Beta-adrenergic Blockers Market, By Region, 2021-2029 (USD Mllion)
19 Vasodilators Market, By Region, 2021-2029 (USD Mllion)
20 Angiotensin-converting Enzyme (ACE) Inhibitors Market, By Region, 2021-2029 (USD Mllion)
21 Angiotensin-receptor Blockers Market, By Region, 2021-2029 (USD Mllion)
22 Analgesics Market, By Region, 2021-2029 (USD Mllion)
23 Thrombolytics Market, By Region, 2021-2029 (USD Mllion)
24 Global Myocardial Infarction Market: By Route of Administration Scope Key Takeaways
25 Global Myocardial Infarction Market, By Route of Administration Segment: Revenue Growth Analysis
26 Oral Market, By Region, 2021-2029 (USD Mllion)
27 Injectable Market, By Region, 2021-2029 (USD Mllion)
28 Global Myocardial Infarction Market: By Distribution Channel Scope Key Takeaways
29 Global Myocardial Infarction Market, By Distribution Channel Segment: Revenue Growth Analysis
30 Hospital Pharmacies Market, By Region, 2021-2029 (USD Mllion)
31 Retail Pharmacies Market, By Region, 2021-2029 (USD Mllion)
32 Online Pharmacies Market, By Region, 2021-2029 (USD Mllion)
33 Regional Segment: Revenue Growth Analysis
34 Global Myocardial Infarction Market: Regional Analysis
35 North America Myocardial Infarction Market Overview
36 North America Myocardial Infarction Market, By Drug Class
37 North America Myocardial Infarction Market, By Route of Administration
38 North America Myocardial Infarction Market, By Distribution Channel
39 North America Myocardial Infarction Market, By Country
40 U.S. Myocardial Infarction Market, By Drug Class
41 U.S. Myocardial Infarction Market, By Route of Administration
42 U.S. Myocardial Infarction Market, By Distribution Channel
43 Canada Myocardial Infarction Market, By Drug Class
44 Canada Myocardial Infarction Market, By Route of Administration
45 Canada Myocardial Infarction Market, By Distribution Channel
46 Mexico Myocardial Infarction Market, By Drug Class
47 Mexico Myocardial Infarction Market, By Route of Administration
48 Mexico Myocardial Infarction Market, By Distribution Channel
49 Four Quadrant Positioning Matrix
50 Company Market Share Analysis
51 Bristol-Myers Squibb Co.: Company Snapshot
52 Bristol-Myers Squibb Co.: SWOT Analysis
53 Bristol-Myers Squibb Co.: Geographic Presence
54 Bayer AG: Company Snapshot
55 Bayer AG: SWOT Analysis
56 Bayer AG: Geographic Presence
57 Johnson & Johnson Services Inc.: Company Snapshot
58 Johnson & Johnson Services Inc.: SWOT Analysis
59 Johnson & Johnson Services Inc.: Geographic Presence
60 Sanofi S.A.: Company Snapshot
61 Sanofi S.A.: Swot Analysis
62 Sanofi S.A.: Geographic Presence
63 Novartis International AG: Company Snapshot
64 Novartis International AG: SWOT Analysis
65 Novartis International AG: Geographic Presence
66 ASTRAZENECA PLC.: Company Snapshot
67 ASTRAZENECA PLC.: SWOT Analysis
68 ASTRAZENECA PLC.: Geographic Presence
69 Daiichi Sankyo Co Ltd : Company Snapshot
70 Daiichi Sankyo Co Ltd : SWOT Analysis
71 Daiichi Sankyo Co Ltd : Geographic Presence
72 Boehringer Ingelheim International GmbH: Company Snapshot
73 Boehringer Ingelheim International GmbH: SWOT Analysis
74 Boehringer Ingelheim International GmbH: Geographic Presence
75 Pfizer Inc., Inc.: Company Snapshot
76 Pfizer Inc., Inc.: SWOT Analysis
77 Pfizer Inc., Inc.: Geographic Presence
78 Merck KGaA: Company Snapshot
79 Merck KGaA: SWOT Analysis
80 Merck KGaA: Geographic Presence
81 Other Companies: Company Snapshot
82 Other Companies: SWOT Analysis
83 Other Companies: Geographic Presence
The Global Myocardial Infarction Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Myocardial Infarction Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
